| Status | Awaiting development |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
| ID number | 6129 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 01 December 2023 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 01 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 06 December 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Tislelizumab for untreated unresectable hepatocellular carcinoma. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in early March 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late May 2024. |
For further information on how we select topics for development, please see our page about topic selection